Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53.
García-Echeverría
C
C
Oncology Research and Core Technologies, Novartis Pharma Inc., CH-4002 Basel, Switzerland. carlos.garcia-echeverria@pharma.novartis.com
Chène
P
P
Blommers
M J
MJ
Furet
P
P
D019943:Amino Acid Substitution; D018360:Crystallography, X-Ray; D006801:Humans; D008024:Ligands; D008958:Models, Molecular; D009687:Nuclear Proteins; D010446:Peptide Fragments / Q000737:chemistry; D010455:Peptides / Q000138:chemical synthesis / Q000737:chemistry*; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000378:metabolism; D051736:Proto-Oncogene Proteins c-mdm2; D013329:Structure-Activity Relationship; D016159:Tumor Suppressor Protein p53 / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000378:metabolism
D008024:Ligands; D009687:Nuclear Proteins; D010446:Peptide Fragments; D010455:Peptides; D011518:Proto-Oncogene Proteins; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2